Multiple sclerosis: disease markers accelerate progress

Lancet Neurol. 2004 Jan;3(1):10. doi: 10.1016/s1474-4422(03)00610-0.

Authors

Robert J Fox¹, Richard A Rudick

Affiliation

¹ Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH, Cleveland, USA.

PMID: 14693099
DOI: 10.1016/s1474-4422(03)00610-0

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Apoptosis Regulatory Proteins
Autoantibodies / blood
Biomarkers*
Brain / pathology
Cell Movement / drug effects
Humans
Magnetic Resonance Imaging
Membrane Glycoproteins / genetics
Multiple Sclerosis / drug therapy
Multiple Sclerosis / pathology*
Natalizumab
TNF-Related Apoptosis-Inducing Ligand
Tumor Necrosis Factor-alpha / genetics

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Apoptosis Regulatory Proteins
Autoantibodies
Biomarkers
Membrane Glycoproteins
Natalizumab
TNF-Related Apoptosis-Inducing Ligand
TNFSF10 protein, human
Tumor Necrosis Factor-alpha